3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1
2
Phase EARLY_PHASE1
1
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Other solid neoplasm
2
Gastrointestinal
1
Conditions
Mesothelioma, Malignant
2
Severe combined immunodeficiency with sensitivity to ionizing radiation
1
Interventions
Carboplatin
551
Pemetrexed
404
Cisplatin
401
Paclitaxel
273
Docetaxel
255
Gemcitabine
218
pembrolizumab
191
Bevacizumab
190
Erlotinib Hydrochloride
184
Radiotherapy
181
Etoposide
147
durvalumab
140
Nivolumab
134
Drug Therapy
127
osimertinib
107
atezolizumab
92
Gefitinib
74
Radiosurgery
72
anlotinib
69
Vinorelbine
68
tislelizumab
52
Irinotecan
51
Ipilimumab
50
130-nm albumin-bound paclitaxel
50
Taxes
48
Surgical Procedures, Operative
46
Cetuximab
46
sintilimab
45
Albumin-Bound Paclitaxel
45
apatinib
44
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
amatuximab
×
Thoracic
×
Clear all
NCT00738582
2022-09-22
Amatuximab
Morphotek
Phase 2
Completed
89 enrolled
12 charts
NCT02357147
2020-03-17
ARTEMIS
Morphotek
Phase 2
Terminated
124 enrolled
10 charts